1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Page describes a rolling monthly deadline (20th of each month), not March 31 2026. The program is the NYS Matching Grants Leverage Program, not 'Biomedical Innovation Centers Grants'.
Biomedical Innovation Centers Grants is a grant from Empire State Development (NY State), through the Division of Science, Technology and Innovation (NYSTAR), that funds early-stage technology development and commercialization efforts by small businesses and startups in New York State.
The program provides matching grant support to leverage federal R&D funding, helping applicants strengthen proposals to federal agencies, foundations, and other grant-making organizations. The goal is to attract more federal research and development dollars to support life science and biomedical innovation in New York. Eligible applicants are small businesses and startups in New York State.
Awards range from $100,000 to $500,000. Applications are accepted monthly with a submission deadline of the 20th of each month. The most recent deadline listed is March 31, 2026.
Get alerted about grants like this
Save a search for “Empire State Development (NY State)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NYS Matching Grants Leverage Program | Center for Biotechnology – Stony Brook University Whether your personal interests are in supporting innovation , bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy , the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients. Give to the Center for Biotechnology online through the Stony Brook Foundation.
Contributions can be made to our Fund for Excellence . More information about donating through the Stony Brook Foundation can be found here . Center for Biotechnology – Stony Brook University NYS Matching Grants Leverage Program NYSTAR reviews and coordinates requests for New York State matching grants and support letters to strengthen applicants’ proposals to federal agencies, foundations, and other grant-making organizations.
The purpose of this program is to attract more federal R&D funding to support technology development and commercialization efforts in New York State. While funding is available, NYSTAR will accept applications monthly with a submission deadline of the 20th. The first Round will have a deadline for application submission of January 20, 2022.
Learn more and apply here: https://esd. ny.
gov/matching-grants-leverage-program [category__not_in] => Array [post_parent__in] => Array [post_parent__not_in] => Array [author__not_in] => Array [search_columns] => Array [update_post_term_cache] => 1 [update_menu_item_cache] => [lazy_load_term_meta] => 1 [update_post_meta_cache] => 1 [comments_per_page] => 50 [tax_query] => WP_Tax_Query Object [table_aliases:protected] => Array [primary_table] => wp_posts [primary_id_column] => ID [meta_query] => WP_Meta_Query Object [table_aliases:protected] => Array [clauses:protected] => Array [has_or_relation:protected] => [request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.
ID WHERE 1=1 AND wp_posts. post_type = 'post' AND ((wp_posts. post_status = 'publish')) [post_date] => 2025-07-17 10:27:09 [post_date_gmt] => 2025-07-17 14:27:09 The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development 's Division of Science, Technology and Innovation (NYSTAR) , a recognition that comes with $1 million in annual funding over the next ten years.
The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships. “The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology.
“This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry. ” Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem.
By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state. ” The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system.
Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine.
The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem.
Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy. Dowload the full press release here .
[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology [post_name] => redesignation2025 [post_modified] => 2025-07-21 14:51:44 [post_modified_gmt] => 2025-07-21 18:51:44 [post_content_filtered] => [guid] => https://centerforbiotechnology. org/?
p=4906 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island.
To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities.
This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond. The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources.
This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation.
Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs.
This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions.
By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization. Read the press release of Governor Hochul's announcement here: https://www. governor.
ny. gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy [post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [guid] => https://centerforbiotechnology. org/?
p=4488 [post_date] => 2015-11-23 20:09:45 [post_date_gmt] => 2015-11-23 20:09:45 [post_content] => Biotechnology Strategist Brian McCarthy and Pharma Executive Gian Luca Araldi selected to launch new bioscience companies STONY BROOK, N. Y.
– November 23, 2015 – The Center for Biotechnology at Stony Brook University announced today the appointment of Brian McCarthy, PhD and Gian Luca Araldi, PhD, as BioEntrepreneurs-In-Residence (B-EIR) for the Long Island Bioscience Hub.
The Long Island Bioscience Hub is a National Institutes of Health-designated Research Evaluation and Commercialization Hub, and represents a partnership between Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory, to commercialize technology emerging from their institutions. Drs.
McCarthy and Araldi have broad bioscience industry experience and comprehensive knowledge of commercializing academic technologies. In their roles as BEIR they will identify technologies that have the potential to support company formation in the region. Each brings unique skills and perspectives to technology assessment and bioscience-startups.
Dr. McCarthy is a senior biotechnology strategist with operational, start-up, development, and financial expertise. He currently serves as a business advisor to Gismo Therapeutics Inc. and VP of Business and Clinical Development at Viatar CTC Solutions Inc. Prior to his Wall Street and entrepreneurial career, Dr. McCarthy was a faculty member at Cornell University Medical College and the National Naval Medical Center.
Dr. McCarthy received his PhD in Neurobiology from Stony Brook University. Dr. Araldi is a pharmaceutical and biotechnology executive with more than 25 years of experience ranging from basic research through clinical development at major pharmaceutical companies including Glaxo, Forest Laboratories and Merck-Serono.
Dr. Araldi has been involved in the development of key medicines such as Teflaro®, Dutogliptin®, Gavestinel®, Sanfetrinem® and Sanfetrinem® Cilexetil and is the inventor of 113 granted patents. Dr. Araldi received doctorate degrees in Organic Chemistry and Pharmacy from the University of Parma (Italy) and recently received his M. B.
A. in Finance from Long Island University Post. “The Long Island Bioscience Hub is excited to announce the appointments of Drs.
McCarthy and Araldi as BioEntrepreneurs-in-Residence” Diane Fabel, Director of Operations for the Center for Biotechnology stated. “They join a talented roster of five existing BioEntrepreneurs in Residence at the Center for Biotechnology who are well on their way to commercializing technologies and building their companies. ” As B-EIRs Drs.
McCarthy and Araldi are tasked with identifying technology or technologies from within the partner institutions that will create the foundation for licensing and company formation. They will have the support of the LIBH business and technology development staff, as well as the support of external industry advisors to develop successful commercialization strategies.
The LIBH can also provide access to a competitive pool of technology development funding to help move their technologies down a commercial pathway. Ultimately, the goal is to help the company position itself prepare for SBIR/STTR grant opportunities, and Angel and VC investment.
[post_title] => Long Island Bioscience Hub Selects Bioentrepreneurs-In-Residence [post_name] => long-island-bioscience-hub-selects-bioentrepreneurs-in-residence [post_modified] => 2016-03-29 20:13:28 [post_modified_gmt] => 2016-03-29 20:13:28 [post_content_filtered] => [guid] => http://centerforbiotechnology. org/?
p=2062 [post_date] => 2019-01-24 15:24:44 [post_date_gmt] => 2019-01-24 15:24:44 [post_content] => BARDA’s DRIVe is pleased to announce the expansion of its market research effort to identify potential partners and capture feedback to support its newest novel public-private partnership, DRIVe Ventures .
DRIVe Ventures will work with corporate venture capital partners to invest in promising products, driving them to the marketplace to transform and enhance national health security. BARDA DRIVe seeks feedback on a potential new novel public-private partnership that leverages venture capital practices and methods to disrupt the way BARDA invests in health security innovation. Learn more .
[post_title] => Request for Information: BARDA DRIVe Ventures [post_excerpt] => BARDA DRIVe wants to hear from the venture capital community – looking for feedback to support its newest novel public-private partnership, DRIVe Ventures.
[comment_status] => closed [post_name] => request-for-information-barda-drive-ventures [post_modified] => 2019-04-09 14:41:07 [post_modified_gmt] => 2019-04-09 14:41:07 [post_content_filtered] => [guid] => http://centerforbiotechnology. org/?
p=3131 [post_date] => 2023-03-02 16:46:18 [post_date_gmt] => 2023-03-02 16:46:18 A second-generation taxane conjugate in a nanoemulsion formulation (called NE-DHA-SBT-1214) developed by Stony Brook University Distinguished Professor Iwao Ojima in his chemistry laboratory and through the Institute of Chemical Biology & Drug Discovery (ICB&DD) and licensed to Dr. James Egan, has received a $24 million investment to be taken to phase 2a development.
Preclinical results have persuaded TVM Capital Life Science to invest in the technology via Recurv Pharma. [post_title] => Anti-Cancer Agent Developed at SBU Shows Great Promise Against Tumors, Receives $24M Investment [post_excerpt] => TVM Capital Life Science to invest $24M in Recurv Pharma to develop an SBU technology.
[comment_status] => closed [post_name] => anti-cancer-agent-developed-at-sbu-shows-great-promise-against-tumors-receives-24m-investment [post_modified] => 2024-08-22 11:35:16 [post_modified_gmt] => 2024-08-22 15:35:16 [post_content_filtered] => [guid] => https://centerforbiotechnology. org/?
p=4032 [post_date] => 2025-07-17 10:27:09 [post_date_gmt] => 2025-07-17 14:27:09 The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development 's Division of Science, Technology and Innovation (NYSTAR) , a recognition that comes with $1 million in annual funding over the next ten years.
The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships. “The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology.
“This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry. ” Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem.
By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state. ” The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system.
Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine.
The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem.
Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy. Dowload the full press release here .
[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology [post_name] => redesignation2025 [post_modified] => 2025-07-21 14:51:44 [post_modified_gmt] => 2025-07-21 18:51:44 [post_content_filtered] => [guid] => https://centerforbiotechnology. org/?
p=4906 [max_num_comment_pages] => 0 [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array [1] => query_vars_changed [compat_methods:WP_Query:private] => Array [query_cache_key:WP_Query:private] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
Long Island Bioscience Hub Selects Bioentrepreneurs-In-Residence Request for Information: BARDA DRIVe Ventures Anti-Cancer Agent Developed at SBU Shows Great Promise Against Tumors, Receives $24M Investment
Based on current listing details, eligibility includes: Small businesses and startups in New York State Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $100,000 - $500,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is March 31, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.